A breakthrough in the fight against greenhouse gases: Politecnico di Milano’s study on the cover of Angewandte Chemie
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Apr-2025 04:08 ET (22-Apr-2025 08:08 GMT/UTC)
Peptides formed during cheese ripening are crucial for the full-bodied flavor of aged cheeses, known as kokumi. A research team led by the Leibniz-Institute for Food Systems Biology at the Technical University of Munich has now developed a new method to analyze these flavor-relevant peptides precisely, quickly, and efficiently. Based on more than 120 cheese samples, the team has also created a database that can be used in the future to predict flavor development during cheese ripening.
Eye care specialists could see artificial intelligence help in diagnosing infectious keratitis (IK), a leading cause of corneal blindness worldwide, as a new study published in eClinicalMedicine finds that deep learning models showed similar levels of accuracy in identifying infection.
A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence, detects potential errors in medication delivery.
In a test, the video system recognized and identified, with high proficiency, which medications were being drawn in busy clinical settings. The AI achieved 99.6% sensitivity and 98.8% specificity at detecting vial-swap errors.
The findings are reported Oct. 22 in npj Digital Medicine.
The system could become a critical safeguard, especially in operating rooms, intensive-care units and emergency-medicine settings, said co-lead author Dr. Kelly Michaelsen, an assistant professor of anesthesiology and pain medicine at the University of Washington School of Medicine.
Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, a new study describes the development of a biologic, a drug derived from natural biological systems, that targets a mutant cancer protein called HER2 (human epidermal growth factor receptor 2) without attacking its nearly identical normal counterpart on healthy cells. Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, a new study describes the development of a biologic, a drug derived from natural biological systems, that targets a mutant cancer protein called HER2 (human epidermal growth factor receptor 2) without attacking its nearly identical normal counterpart on healthy cells.